Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234738 | 1.00 | ASIC3 (0.43) | ASIC3HTR2CHTR2BKMT2APNMT | |
| SCHEMBL236559 | 0.92 | HTR2C (0.44) | ASIC3HTR2CHTR2BKMT2AEGFR | |
| SCHEMBL236447 | 0.91 | HTR2C (0.49) | ASIC3HTR2CHTR2BKMT2AEGFR | |
| Hydrochloric Acid SCHEMBL613637 | 0.89 | HTR2C (0.51) | ASIC3HTR2CHTR2BKMT2AEGFR | |
| SCHEMBL236582 | 0.88 | KMT2A (0.36) | KMT2APNMTGRM4HRH1 | |
| SCHEMBL232886 | 0.85 | HTR2C (0.36) | HTR2CHTR2B | |
| SCHEMBL235826 | 0.84 | L3MBTL1 (0.36) | HTR2CHTR2BKMT2APNMTGRM4 | |
| SCHEMBL236434 | 0.84 | FFAR1 (0.43) | KMT2AHRH1 | |
| SCHEMBL236428 | 0.84 | FFAR1 (0.43) | KMT2AHRH1 | |
| SCHEMBL233182 | 0.84 | KCNH2 (0.40) | HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450527-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | ASIC3 2052/4885HTR2C 472/4885HTR2B 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.